Fmc Corp (FMC) · Oct 15, 2026 · Guidance
Guidance cut — Q3 revenue $65–125M vs published consensus of ~$869M
FMC cuts third-quarter guidance dramatically, citing weak channel demand, excess high-priced inventory, major commercial actions and possible impairment.
FMC is a crop-protection company trying to move past the post-patent Rynaxypyr transition, channel destocking and weaker legacy-product demand while funding new active-ingredient growth and reducing debt. Its prior 2026 plan depended on modest volume recovery, lower manufacturing costs and stronger sales of newer products.
This is an extreme guidance cut, not a routine quarterly adjustment. FMC now expects third-quarter revenue of just $65–125 million and Adjusted EBITDA of negative $510–565 million, including $625–675 million from commercial actions. That revenue range is dramatically below the published consensus of roughly $869 million, making this a fundamental demand and inventory event rather than a minor miss.
| Measure | New Q3 2026 expectation | External comparison |
|---|---|---|
| Revenue | $65–125M (Press release) | Published consensus: ~$869M |
| Adjusted EBITDA | $(510)–$(565)M (Press release) | No reliable published consensus located |
| Commercial-action impact | $(625)–$(675)M (Press release) | — |
The immediate problem is trapped channel inventory, amplified by falling market prices. Distributors are keeping inventories exceptionally lean, while some FMC products remain priced above current market levels because of generic competition and changing competitive conditions. 〔0〕 This means the company is sacrificing near-term revenue and profitability to clear product and restart replenishment demand.
The commercial reset may improve competitiveness, but it confirms that the old pricing model is no longer working. FMC plans to lower prices on selected channel inventory and reduce the gap between high gross prices and rebates in the United States. 〔1〕 The filing presents these actions as a bridge to 2027 and beyond, but the cost and scale of the reset show that the channel issue is materially deeper than the prior incremental fixes implied.
Balance-sheet risk is now part of the operating story. FMC expects to remain in covenant compliance at September 30, but it plans to discuss further covenant flexibility with lenders as the actions are implemented. It has also identified a triggering event for a possible material intangible-asset impairment, although the amount is not yet estimable and would be non-cash. 〔2〕
The next disclosure matters because this release leaves the full-year reset unresolved. FMC will provide finalized third-quarter results and updated 2026 guidance on October 29, 2026, followed by preliminary 2027 and 2028 expectations on October 30, 2026. 〔3〕
Bottom line: This filing materially sets back FMC’s recovery story: demand is weaker, inventory is more impaired economically, and clearing the channel requires a very expensive pricing reset. The possible impairment and lender discussions make the problem broader than a single weak quarter.
Q3 earnings October 29; 2027–2028 outlook October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!